Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative areas of the pharmaceutical indus

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.

In a press release, Lilly announced that in its latest trial comparing its medication, Zepbound, to Wegovy, made by Novo Nordisk, people randomly assigned to receive Zepbound lost about 20% of their body weight after about 18 months, while those taking Wegovy lost nearly 14% of their body weight.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly said in a statement Wednesday. On average, Zepbound led to a superior weight loss of 20.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks.

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.